Researchers at the Germans Trias i Pujol Research Institute and Hospital have characterized and developed a new study model using Drosophila that will enable the evaluation of various infectious agents.

The Clinical and Experimental Microbiology Unit (UMCiE) at the Germans Trias i Pujol Research Institute (IGTP), in collaboration with the Comparative Medicine and Bioimage Center of Catalonia (CMCiB), a strategic project of the institute, has spent years studying and refining infection. techniques in Drosophila melanogaster flies.

These organisms, commonly known as fruit flies, present multiple experimental advantages. They have a short life cycle, low maintenance costs, are easily genetically manipulated, and approximately 65% ​​of their genes have human homologues, along with some shared physiological systems. Furthermore, using Drosophila helps reduce the use of vertebrate animals in research, providing an ethical alternative for preliminary experiments.

UMCiE researchers are using D. melanogaster as an experimental model to evaluate new vaccines or antibiotics after demonstrating their efficacy in vitro (in the laboratory), before moving on to studies involving animals such as mice.

Recently, they have published two articles in Frontiers in Microbiology and Frontiers in Immunologylaying the groundwork for using this model for different infections and evaluating its innate immunity against infections by Candida albicans.

The Frontiers in Microbiology The article outlines the establishment of the experimental infection model, reviewing a wide range of studies on the subject and detailing the research group’s experience in this field. It describes all the techniques applicable, both for infection and drug administration, and how to evaluate them. The study encompasses the model for different infections and serves as the foundation for a platform that the group is developing to test new antibiotics.

In the other article, UMCiE scientists assess innate immunity against infections by Candida albicans, a yeast causing challenging-to-treat infections in immunocompromised patients. They have analyzed the impact that enhanced immune response can have on the progression of highly virulent C. albicans infections. Paradoxically, although pre-immunization can control yeast growth, it does not prevent the fly’s death. This is due to an immune storm akin to what occurs in some patients with COVID-19.

Thus, the proposed Drosophila model also allows for the design of new therapeutic approaches that not only target pathogen destruction but also consider medications to control uncontrolled immune responses, known as “host-directed therapies.” These could include anti-inflammatory drugs, corticosteroids, or other immunosuppressants.

Pere-Joan Cardona, leader of UMCiE at IGTP, head of the Microbiology Service at Germans Trias i Pujol University Hospital and CIBER of Respiratory Diseases (CIBERES) member, states, “These publications mark a significant milestone for the group in using the Drosophila infection model.

“We have established a platform where we can quickly and cost-effectively evaluate various candidates against infectious agents, whether they be antibiotics or immunomodulatory drugs. This aligns with CMCiB’s mission to replace and reduce the use of laboratory animals like mice, representing a major achievement and positioning us as a reference group in this field.”

Provided by Germans Trias i Pujol Research Institute